US5047524A
(en)
*
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5262530A
(en)
*
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5166387A
(en)
*
|
1990-01-12 |
1992-11-24 |
Applied Biosystems, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs with thiuram disulfides
|
WO1992013629A1
(en)
*
|
1991-01-31 |
1992-08-20 |
Wayne State University |
A method for analyzing an organic sample
|
US5512668A
(en)
*
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
US6033909A
(en)
*
|
1992-01-22 |
2000-03-07 |
Hoechst Aktiengesellschaft |
Oligonucleotide analogs, their preparation and use
|
US5646261A
(en)
*
|
1992-01-22 |
1997-07-08 |
Hoechst Aktiengesellschaft |
3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
|
KR930016437A
(ko)
*
|
1992-01-22 |
1993-08-26 |
귀틀라인, 슈미트 |
올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
|
US5627277A
(en)
*
|
1992-12-16 |
1997-05-06 |
Hybridon, Inc. |
Method for analyzing oligonucleotide analogs
|
US5643717A
(en)
*
|
1992-12-16 |
1997-07-01 |
Hybridon, Inc. |
Substrate useful for separating modified oligonucleotides
|
US5506103A
(en)
*
|
1993-11-16 |
1996-04-09 |
Hybridon, Inc. |
Method for detecting charged oligonucleotides in biological fluids
|
JPH09508281A
(ja)
*
|
1994-01-26 |
1997-08-26 |
ハイブリドン,インコーポレイテッド |
生物学的液体中のppbより下のレベルのオリゴヌクレオチドの検出方法
|
US5510476A
(en)
*
|
1994-07-07 |
1996-04-23 |
Isis Pharmaceuticals, Inc. |
Carbocation scavenging during oligonucleotide synthesis
|
US5990300A
(en)
*
|
1994-09-02 |
1999-11-23 |
Andrew C. Hiatt |
Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US5872244A
(en)
*
|
1994-09-02 |
1999-02-16 |
Andrew C. Hiatt |
3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
|
US6232465B1
(en)
*
|
1994-09-02 |
2001-05-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US6214987B1
(en)
|
1994-09-02 |
2001-04-10 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
|
US5763594A
(en)
*
|
1994-09-02 |
1998-06-09 |
Andrew C. Hiatt |
3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
|
US5750341A
(en)
|
1995-04-17 |
1998-05-12 |
Lynx Therapeutics, Inc. |
DNA sequencing by parallel oligonucleotide extensions
|
US5705621A
(en)
*
|
1995-11-17 |
1998-01-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
|
US6660233B1
(en)
|
1996-01-16 |
2003-12-09 |
Beckman Coulter, Inc. |
Analytical biochemistry system with robotically carried bioarray
|
ES2114504B1
(es)
*
|
1996-09-13 |
1999-02-01 |
Univ Madrid Autonoma |
Metodo para la sintesis enzimatica de desoxioligonucleotidos en soporte solido.
|
AU5318398A
(en)
*
|
1996-11-07 |
1998-05-29 |
Novartis Ag |
Process for the preparation of an oligomeric compound
|
US5902881A
(en)
*
|
1997-03-03 |
1999-05-11 |
Isis Pharmaceuticals, Inc. |
Reagent useful for synthesizing sulfurized oligonucleotide analogs
|
US5760209A
(en)
*
|
1997-03-03 |
1998-06-02 |
Isis Pharmaceuticals, Inc. |
Protecting group for synthesizing oligonucleotide analogs
|
US7427678B2
(en)
|
1998-01-08 |
2008-09-23 |
Sigma-Aldrich Co. |
Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
|
US6020475A
(en)
*
|
1998-02-10 |
2000-02-01 |
Isis Pharmeuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
US7273933B1
(en)
*
|
1998-02-26 |
2007-09-25 |
Isis Pharmaceuticals, Inc. |
Methods for synthesis of oligonucleotides
|
US6531590B1
(en)
*
|
1998-04-24 |
2003-03-11 |
Isis Pharmaceuticals, Inc. |
Processes for the synthesis of oligonucleotide compounds
|
US6326478B1
(en)
|
1998-07-08 |
2001-12-04 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
US6867294B1
(en)
*
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6335437B1
(en)
|
1998-09-07 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Methods for the preparation of conjugated oligomers
|
US6169177B1
(en)
|
1998-11-06 |
2001-01-02 |
Isis Pharmaceuticals, Inc. |
Processes for the synthesis of oligomeric compounds
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
US6610842B1
(en)
|
1999-05-06 |
2003-08-26 |
Isis Pharmaceuticals, Inc. |
Processes for the synthesis of oligomers using phosphoramidite compositions
|
US6451998B1
(en)
|
1999-10-18 |
2002-09-17 |
Agilent Technologies, Inc. |
Capping and de-capping during oligonucleotide synthesis
|
US6809195B1
(en)
|
2000-08-16 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotides
|
WO2003003063A2
(en)
*
|
2001-06-28 |
2003-01-09 |
Ia, Inc. |
Fiber-optic sensor array
|
WO2003062452A2
(en)
|
2002-01-23 |
2003-07-31 |
Proligo, Llc |
Methods for the integrated synthesis and purification of oligonucleotides
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
EP1470148B1
(de)
|
2002-02-01 |
2012-07-18 |
Life Technologies Corporation |
Doppelsträngige oligonukleotide
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
AU2003217749A1
(en)
*
|
2002-02-26 |
2003-09-09 |
Pharmacia Corporation |
Sequence detection system calculator
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
US20050009051A1
(en)
*
|
2002-09-27 |
2005-01-13 |
Board Of Regents, The University Of Texas |
Diagnosis of mould infection
|
US7247337B1
(en)
|
2002-12-16 |
2007-07-24 |
Agilent Technologies, Inc. |
Method and apparatus for microarray fabrication
|
EP1585755B1
(de)
|
2002-12-31 |
2015-08-05 |
Sigma-Aldrich Co. LLC |
Verfahren und zusammenstellungen für die tandem-synthese von zwei oder mehr oligonukleotiden auf einen festen träger
|
AU2004212953B2
(en)
|
2003-02-14 |
2010-03-11 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
US20050164211A1
(en)
*
|
2004-01-22 |
2005-07-28 |
Hannah Eric C. |
Carbon nanotube molecular labels
|
EP2290076B1
(de)
|
2004-05-28 |
2015-03-25 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen mit MicroRNA
|
CA2581086C
(en)
|
2004-09-14 |
2023-11-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Method for treatment with bucindolol based on genetic targeting
|
WO2006137941A2
(en)
|
2004-11-12 |
2006-12-28 |
Ambion, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
WO2006110314A2
(en)
|
2005-03-25 |
2006-10-19 |
Ambion, Inc. |
Methods and compositions for depleting abundant rna transcripts
|
US7396676B2
(en)
|
2005-05-31 |
2008-07-08 |
Agilent Technologies, Inc. |
Evanescent wave sensor with attached ligand
|
EP2487240B1
(de)
|
2006-09-19 |
2016-11-16 |
Interpace Diagnostics, LLC |
Mikro-RNA, die differentiell in Pankreaserkrankungen exprimiert sind, und ihre Verwendung
|
EP2145001A2
(de)
|
2006-09-19 |
2010-01-20 |
Asuragen, Inc. |
Von mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulierte gene und stoffwechselwege als ziele für einen therapeutischen eingriff
|
CA2671299A1
(en)
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro rnas
|
US7858772B2
(en)
*
|
2006-12-22 |
2010-12-28 |
Roche Molecular Systems, Inc. |
Compounds and methods for synthesis and purification of oligonucleotides
|
JP5677703B2
(ja)
|
2008-01-10 |
2015-02-25 |
リサーチ ディベロップメント ファウンデーション |
Ehrlichiachaffeensisにのためのワクチンおよび診断
|
BRPI0907637A8
(pt)
|
2008-01-25 |
2018-01-02 |
P53 Inc |
biomarcadores p53
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
CN102272157B
(zh)
|
2008-11-07 |
2015-11-25 |
研究发展基金会 |
用于抑制cripto/grp78复合物形成和信号的组合物和方法
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
JP2012515532A
(ja)
|
2009-01-20 |
2012-07-12 |
ラモット アット テル アビブ ユニバーシティ, リミテッド |
Mir−21プロモーター駆動性標的がん治療
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
US8309710B2
(en)
|
2009-06-29 |
2012-11-13 |
Agilent Technologies, Inc. |
Use of N-alkyl imidazole for sulfurization of oligonucleotides with an acetyl disulfide
|
CN102686728B
(zh)
|
2009-06-29 |
2018-09-18 |
卢米耐克斯公司 |
具有发夹构象的嵌合引物及其使用方法
|
US8642755B2
(en)
|
2009-06-30 |
2014-02-04 |
Agilent Technologies, Inc. |
Use of thioacetic acid derivatives in the sulfurization of oligonucleotides with phenylacetyl disulfide
|
ES2545794T3
(es)
|
2009-08-28 |
2015-09-15 |
Research Development Foundation |
Análogos de urocortina 2 y usos de los mismos
|
WO2011032088A1
(en)
|
2009-09-11 |
2011-03-17 |
Arca Biopharma, Inc. |
Polymorphisms in the pde3a gene
|
ES2587191T3
(es)
|
2009-12-23 |
2016-10-21 |
Arca Biopharma, Inc. |
Métodos y composiciones para enfermedades y afecciones cardiovasculares
|
US20130078614A1
(en)
|
2010-02-12 |
2013-03-28 |
Yonsei University Wonju Industry-Academic Cooperation Foundation |
Probe for hpv genotype diagnosis and analysis method thereof
|
EP2538943B1
(de)
|
2010-02-25 |
2016-03-30 |
Dana-Farber Cancer Institute, Inc. |
Braf-mutationen für resistenz gegen braf-inhibitoren
|
EP3214174B1
(de)
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
Mirna-molekül, das über seine quelle definiert ist, und seine diagnostischen und therapeutischen verwendungen bei mit emt assoziierten krankheiten
|
US20130131148A1
(en)
|
2010-04-12 |
2013-05-23 |
Noam Shomron |
Micro-rna for cancer diagnosis, prognosis and therapy
|
MX342966B
(es)
|
2010-06-09 |
2016-10-19 |
Dana Farber Cancer Inst Inc |
Una mutacion mek1 que confiere resistencia a inhibidores raf y mek.
|
EP3369817A1
(de)
|
2010-07-06 |
2018-09-05 |
InteRNA Technologies B.V. |
Mirna und ihre diagnostischen und therapeutischen verwendungen bei erkrankungen und zuständen im zusammenhang mit melanomen oder bei erkrankungen und zuständen mit einem aktivierten braf-pfad
|
JP6155194B2
(ja)
|
2010-11-17 |
2017-06-28 |
インターペース ダイアグノスティックス リミテッド ライアビリティ カンパニー |
良性甲状腺新生物と悪性甲状腺新生物を区別するためのバイオマーカーとしてのmiRNA
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
CA2826043A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
CA2825981A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
WO2013037065A1
(en)
|
2011-09-13 |
2013-03-21 |
Ottawa Hospital Research Institute |
Microrna inhibitors
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
WO2013063519A1
(en)
|
2011-10-26 |
2013-05-02 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
WO2013095132A1
(en)
|
2011-12-22 |
2013-06-27 |
Interna Technologies B.V. |
Mirna for treating head and neck cancer
|
EP2897633B1
(de)
|
2012-09-18 |
2020-01-01 |
UTI Limited Partnership |
Behandlung von schmerzen durch hemmung von usp5-deubiquitinase
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
WO2014116721A1
(en)
|
2013-01-22 |
2014-07-31 |
The Arizona Board Of Regents For And On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
EP3404116B1
(de)
|
2013-03-15 |
2022-10-19 |
The University of Chicago |
Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
|
US10028902B2
(en)
|
2013-11-08 |
2018-07-24 |
Baylor Research Institute |
Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
|
US11421229B2
(en)
|
2015-02-20 |
2022-08-23 |
Baylor College Of Medicine |
p63 inactivation for the treatment of heart failure
|
US20190177391A1
(en)
|
2016-03-31 |
2019-06-13 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
SG11201901667TA
(en)
|
2016-09-16 |
2019-03-28 |
Bio Path Holdings Inc |
Combination therapy with liposomal antisense oligonucleotides
|
WO2019086603A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
BR112020024083A2
(pt)
|
2018-05-25 |
2021-05-04 |
Arca Biopharma Inc. |
métodos e composições envolvendo bucindolol para o tratamento de fibrilação atrial
|
WO2022097157A2
(en)
|
2020-11-09 |
2022-05-12 |
1E Therapeutics, Ltd. |
Catalytic sequence based methods of treating or preventing bacterial infections
|
WO2022144882A2
(en)
|
2020-12-28 |
2022-07-07 |
1E Therapeutics, Ltd. |
P21 mrna target areas for silencing
|
EP4267742A2
(de)
|
2020-12-28 |
2023-11-01 |
1E Therapeutics, Ltd. |
Auf p21-mrna abzielende dnazyme
|
EP4320445A1
(de)
|
2021-04-08 |
2024-02-14 |
Joslin Diabetes Center, Inc. |
Verfahren zur diagnose und vorhersage von nierenabbau
|